NCT02863055终止2 期
Nintedanib as Maintenance Treatment of Pleural Malignant Mesothelioma (NEMO): a Randomized Double Blinded Phase II Study of the EORTC Lung Cancer Group
European Organisation for Research and Treatment of Cancer - EORTC8 个研究点 分布在 3 个国家目标入组 37 人开始时间: 2018年2月4日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 37
- 试验地点
- 8
- 主要终点
- Progression-free survival
研究概览
简要总结
This is a multicenter, randomized, 1:1, double blinded phase II trial. Patients with unresectable malignant pleural mesothelioma (MPM) will be randomized between arm A: nintedanib and arm B:placebo
详细描述
This is a multicenter, prospective, double blinded, randomized, two-arm phase II trial aiming to evaluate nintedanib treatment as switch maintenance in patients with unresectable MPM.
After signing of the informed consent and upon confirmation of all eligibility criteria, patients will be randomized 1:1 to:
- Arm A: twice daily nintedanib at a dose of 200 mg until progression or unacceptable toxicities.
- Arm B: matched placebo.
Response evaluation will be performed through CT scans every 8 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histological diagnosis of unresectable Malignant Pleural Mesothelioma (MPM);
- •Response or Stable disease according to modified RECIST criteria [48] after first line platinum-pemetrexed chemotherapy for 4-6 cycles;
- •Last platinum chemotherapy dose administered within 60 days (i.e. randomization must occur within 60 days from the last dose of the last cycle of platinum-pemetrexed chemotherapy);
- •Age >18 years;
- •ECOG performance status (PS) 0-2;
- •Life expectancy of at least 12 weeks in the opinion of the investigator;
- •Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to start of first dose
排除标准
- •prior systemic anticancer therapy including cytotoxic therapy or immune-checkpoint inhibitor, for MPM, other than first line platinum-based doublet chemotherapy;
- •previous extra-pleural pneumonectomy (other forms of previous surgery eg pleurectomy are acceptable);
- •previous Vascular Endothelial Growth Factor (VEGF) inhibitors (eg bevacizumab, sorafenib, etc);
- •treatment with other investigational drugs or treatment in another clinical interventional trial within the past 4 weeks before start of therapy or concomitantly with the trial;
- •patients that, in the opinion of the investigator, have reduced performance status by 2 ECOG levels (e.g. PS 0 to 2 or PS 1 to 3) from beginning to completion of 1st line chemotherapy;
- •radiotherapy (with the exception of palliative radiotherapy) during study or within 4 weeks of start of study drug;
- •known brain metastasis or lepto-meningeal disease. Patients with suspicious neurological symptoms should undergo a CT scan/MRI of the brain to exclude brain metastasisNo active brain metastases (e.g. stable for < 4 weeks;, no adequate previous treatment with radiotherapy;, symptomatic, requiring treatment with anti-convulsants; dexamethasone therapy will be allowed if administered as stable dose for at least one month before randomization); patients with suspicious neurological symptoms should undergo a CT scan/MRI of the brain to assess brain metastasis;
- •leptomeningeal metastases;
- •significant weight loss (> 10 %) within the past 6 weeks prior to treatment in the present trial;
- •pre-existing clinically significant ascites and/or clinically significant pleural effusion;
- •active or history of bleeding complications that would prevent anti-angiogenic therapy
- •centrally located tumors with radiographic evidence (CT or MRI) of local invasion of major blood vessels; typical mediastinal pleural involvement with mesothelioma remains eligible;
- •clinically active cancer other than mesothelioma within 5 years prior to start of study treatment;
- •radiographic evidence of cavitatory or necrotic tumors;
- •unstoppable use of therapeutic anticoagulation (except low dose heparin and/or heparin flush as needed for maintenance of an indwelling intravenous device) or antiplatelet therapy (except for chronic low-dose therapy with acetylsalicylic acid =325mg per day);
- •clinically significant cardiovascular diseases (i.e. hypertension not controlled by medical therapy, unstable angina, history of myocardial infarction within the past 6 months, congestive New York Heart Association (NYHA) II, serious cardiac arrhythmia, clinically significant pericardial effusion)
研究组 & 干预措施
Placebo
Placebo Comparator
Placebo match twice a day per os
干预措施: Placebo (Drug)
Nintedanib
Experimental
200 mg twice a day per os
干预措施: Nintedanib (Drug)
结局指标
主要结局
Progression-free survival
时间窗: 6 months
From randomization until progression or death
次要结局
- Overall Response Rate(6 months)
- Overall survival(12 months)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
2 期
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is RecurrentRecurrent Pleural Malignant MesotheliomaStage IV Pleural MesotheliomaNCT02568449Barbara Ann Karmanos Cancer Institute20
已完成
3 期
Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)Colorectal NeoplasmsNCT02149108Boehringer Ingelheim768
已完成
2 期
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib TherapyMantle Cell LymphomaNCT01599949Janssen Research & Development, LLC120
已完成
2 期
Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine TumorsCarcinoid TumorMetastatic Carcinoid TumorNeuroendocrine NeoplasmNCT02399215Roswell Park Cancer Institute32
进行中（未招募）
1 期
Treatment of no squamous non small cell lung cancero squamous non small cell lungMedDRA version: 18.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-000475-27-FRCHU de Limoges59